These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18754041)

  • 1. Extended release of adenovirus from silica implants in vitro and in vivo.
    Kangasniemi L; Koskinen M; Jokinen M; Toriseva M; Ala-Aho R; Kähäri VM; Jalonen H; Ylä-Herttuala S; Moilanen H; Stenman UH; Diaconu I; Kanerva A; Pesonen S; Hakkarainen T; Hemminki A
    Gene Ther; 2009 Jan; 16(1):103-10. PubMed ID: 18754041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
    Palmer DH; Chen MJ; Searle PF; Kerr DJ; Young LS
    Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
    Hakkarainen T; Rajecki M; Sarparanta M; Tenhunen M; Airaksinen AJ; Desmond RA; Kairemo K; Hemminki A
    Clin Cancer Res; 2009 Sep; 15(17):5396-403. PubMed ID: 19706820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
    Särkioja M; Pesonen S; Raki M; Hakkarainen T; Salo J; Ahonen MT; Kanerva A; Hemminki A
    Gene Ther; 2008 Jun; 15(12):921-9. PubMed ID: 18401431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
    Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
    Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.
    Duerner LJ; Schwantes A; Schneider IC; Cichutek K; Buchholz CJ
    Gene Ther; 2008 Nov; 15(22):1500-10. PubMed ID: 18509380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.
    Kanerva A; Zinn KR; Peng KW; Ranki T; Kangasniemi L; Chaudhuri TR; Desmond RA; Wang M; Takayama K; Hakkarainen T; Alfthan H; Stenman UH; Curiel DT; Hemminki A
    Gene Ther; 2005 Jan; 12(1):87-94. PubMed ID: 15385953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
    Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.
    Ji X; Zhang J; Cheng L; Wei F; Li H; Liu X; Chen X; Li C; Wang Y; Huang Q
    Exp Eye Res; 2009 Aug; 89(2):193-9. PubMed ID: 19328781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
    Wang H; Satoh M; Abe H; Sunamura M; Moriya T; Ishidoya S; Saito S; Hamada H; Arai Y
    Urology; 2006 Sep; 68(3):674-81. PubMed ID: 16979729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer.
    Kangasniemi L; Kiviluoto T; Kanerva A; Raki M; Ranki T; Sarkioja M; Wu H; Marini F; Höckerstedt K; Isoniemi H; Alfthan H; Stenman UH; Curiel DT; Hemminki A
    Clin Cancer Res; 2006 May; 12(10):3137-44. PubMed ID: 16707613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer.
    Yan Y; Rubinchik S; Wood AL; Gillanders WE; Dong JY; Watson DK; Cole DJ
    Mol Ther; 2006 Feb; 13(2):357-65. PubMed ID: 16226492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From gene therapy to virotherapy for ovarian cancer.
    Stoff-Khalili MA; Dall P; Curiel DT
    Minerva Ginecol; 2004 Dec; 56(6):503-14. PubMed ID: 15729203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
    Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
    Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD.
    Youn JI; Park SH; Jin HT; Lee CG; Seo SH; Song MY; Lee CW; Sung YC
    Cancer Gene Ther; 2008 Nov; 15(11):703-12. PubMed ID: 18600258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings: therapeutic effect on metastatic ovarian cancer.
    Yoshihara C; Hamada K; Koyama Y
    Oncol Rep; 2010 Mar; 23(3):733-8. PubMed ID: 20127013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oncolytic viruses for genetic therapy of gastrointestinal tumors].
    Bitzer M; Lauer UM
    Z Gastroenterol; 2003 Jul; 41(7):667-74. PubMed ID: 12858239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.